Biomoda, a cancer diagnostics company, has signed an agreement with the University of Texas Health Science Center (UT) to optimize the CyPath diagnostic assay for lung cancer.
UT Health Science Center performs biomedical research on accelerating, facilitating, increasing, developing, and dissemination of biomedical solutions turning scientific research into clinical practice.
Health Science Center Research vice president Brian Herman said they will be working with Biomoda to bring its cancer diagnostic tests to the front end of medical treatment in order to use medical expertise and resources as efficiently and effectively as possible.
Biomoda president John Cousins said the company is focused on optimization of its assay to include automating sample reading through flow cytometry and refining the use of fluorescent microscopy to identify cancer cell types and pre-cancerous cells.
Biomoda CEO Maria Zannes said they will benefit from the Health Science Center’s extensive resources for their ongoing optimization work in preparation for the multi-site pivotal trial.